# Dupilumab

## DUPIXENT inj 300mg/2mL

| TAH Drug Code      | [IDUPI](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IDUPI)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Dupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Dosing             | Atopic dermatitis, Moderate to severe Adult, initial, 600 mg (two 300 mg injections) SC, then 300 mg SC every other week Adolescents 12 to 17 Years Old, if <60kg 400 mg (two 200 mg injections) SC, then 200 mg SC every other week. If>60kg 600 mg (two 300 mg injections) SC, then 300 mg SC every other week. Concomitant therapy: Use with or without topical steroids; reserve concomitant use with topical calcineurin inhibitors for problem areas only (eg, face, neck, intertriginous and genital areas Asthma (Moderate to Severe), Adjunct; oral corticosteroid-dependent (12 years or older) Loading, 400 mg (two 200 mg injections) SC followed by 200 mg every other week or an initial loading dose of 600 mg (two 300 mg injections) SC followed by 300 mg every other week. For patients with oral corticosteroid-dependent asthma or with comorbid moderate-to-severe atopic dermatitis, start with the 600-mg dose followed by 300 mg every other week |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Contraindications  | Known hypersensitivity to dupilumab or any component of the formulation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Adverse Effects    | >10%: Local: Injection site reaction (10% to 18%) 1% to 10%: Gastrointestinal: Oral herpes simplex infection (4%) Hematologic & oncologic: Eosinophilia (<2%) Immunologic: Antibody development (6% to 9%; neutralizing: 2% to 4%) Infection: Herpes simplex infection (2%) Ophthalmic: Conjunctivitis (10%), eye pruritus (1%) Respiratory: Oropharyngeal pain (2%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Pregnancy          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Lactation          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

## Dupixent inj 200mg/1.14mL

##### 臨採

| TAH Drug Code      | [IDUPI2](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IDUPI2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|:-------------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Atopic Dermatitis: For moderate to severe atopic dermatitis in adults and children (6 months and older) with inadequate response to topical prescription treatments or unsuitable for such therapy. Can be used with or without topical corticosteroid therapy. Asthma: As add-on maintenance therapy for asthma patients (6 years and older) with eosinophilic phenotype or corticosteroid-dependent asthma, who are inadequately controlled on medium to high-dose inhaled corticosteroids (ICS) and a second controller (e.g., LABA, LTRA, LAMA, or methylxanthines), or on high-dose ICS alone. Chronic Rhinosinusitis with Nasal Polyps: As add-on maintenance therapy for adults with chronic rhinosinusitis with nasal polyps (CRSwNP) who remain uncontrolled despite nasal corticosteroid therapy.                                                                                                                                      |
| Dosing             | Atopic dermatitis - Adults: 600mg subQ once, then 300mg every 2 weeks. Children (6 months - 5 years): 5 - < 15 kg: 200mg every 4 weeks (Q4W) 15 - < 30 kg: 300mg every 4 weeks (Q4W) Children (6-17 years): 15 - < 30 kg: 600mg (300mg x 2) initially, then 300mg every 4 weeks (Q4W) 30 - < 60 kg: 400mg (200mg x 2) initially, then 200mg every 2 weeks (Q2W) > 60 kg: 600mg (300mg x 2) initially, then 300mg every 2 weeks (Q2W) Asthma - Adults and children (>12 years): Initial 400mg (200mg x 2), then 200mg every 2 weeks (Q2W). Patients with steroid-dependent asthma, moderate to severe atopic dermatitis, or chronic rhinosinusitis with nasal polyps: Initial 600mg (300mg x 2), then 300mg every 2 weeks (Q2W). Children (6-11 years) - 15 to < 30 kg: 100mg every 2 weeks (Q2W) or 300mg every 4 weeks (Q4W). > 30 kg: 200mg every 2 weeks (Q2W). Chronic rhinosinusitis with nasal polyps - Adults: 300mg every 2 weeks (Q2W). |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Contraindications  | Known hypersensitivity to dupilumab or any of its excipients.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Adverse Effects    | Common: Injection site disorder (Adult, 6-18%; adult and pediatric, 38%), Oral herpes simplex infection (3-4%), Pain in throat and mouth (2%), Herpes simplex (Excluding oral and ophthalmic herpes simplex, 1-2%), Blepharitis (Up to 5%), Conjunctivitis (Asthma, 1.5%; atopic dermatitis, 9-20%; chronic rhinosinusitis with nasal polyposis, 2%; prurigo nodularis, 4%), Dry eyes (Up to 2%), Itching of eye (1-2%), Keratitis (Atopic dermatitis, up to 4%) Serious: Arterial thromboembolism (0-0.9%), Vasculitis, Eosinophil count above the reference range (1-2%), Hypersensitivity reaction (<1%), Arthralgia (2-3%), Pulmonary eosinophilia, Angioedema, Helminth infection                                                                                                                                                                                                                                                           |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Low Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

